Justin Joy

219 posts

Justin Joy

Justin Joy

@HughHFrEFner

Cardiology Specialty Pharmacist - Emory PGY1/Duke Cards PGY2 || Here for the trials and fibrillations

Katılım Eylül 2019
206 Takip Edilen175 Takipçiler
Justin Joy
Justin Joy@HughHFrEFner·
We're looking for a Cardiology Clinical Specialist Pharmacist to join our Emory Ambulatory Care team! If you're interested or know someone who might be a great fit please apply! Feel free to message me with any questions social.icims.com/viewjob/pt1741…
English
1
0
1
130
Justin Joy retweetledi
American College of Cardiology
American College of Cardiology@ACCinTouch·
Outpatient loading of sotalol through a pharmacist-led, protocol-driven antiarrhythmic clinic is safe & feasible w/ high adherence rates using personal remote ECG recordings. Read the journal scan to learn more: bit.ly/4g6ANOH #JACCCEP
American College of Cardiology tweet media
English
3
27
84
12.3K
Justin Joy retweetledi
John Mandrola, MD
John Mandrola, MD@drjohnm·
“When compared to equivalent doses of ARB/ACEI, SV is not superior in reducing mortality and worsening heart failure. SV is superior when compared to sub-equivalent doses of ACEI.” Grin 👆
Batman-Echo@echo_batman

Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials | Europ Jour of Clinical Pharma link.springer.com/article/10.100…

English
2
10
51
26.1K
Justin Joy retweetledi
Cait E. Kulig 🇺🇦
Cait E. Kulig 🇺🇦@Cait_Centra·
❗ ❗❗for all my educator friends: maybe i'm late to the game but how cool is this feature on PPT?! It's called cameo, you can record yourself and embed it into each slide so that you can narrate each slide automatically when re-watched with both audio and video. @accpedtrprn
Cait E. Kulig 🇺🇦 tweet mediaCait E. Kulig 🇺🇦 tweet media
English
0
2
12
1.1K
Justin Joy
Justin Joy@HughHFrEFner·
The advancement of clinical pharmacy and healthcare relies on constructive debate. One doesn't need to agree with Dr. Prasad to appreciate the opportunity to engage with his perspectives. It's disappointing to see an occasion for meaningful dialogue and learning pass us by
English
1
1
7
329
Justin Joy retweetledi
John Mandrola, MD
John Mandrola, MD@drjohnm·
Disinviting speakers is antithetical to science. Better would have been to engage w ideas. Think. Argue. Persuade. @VPrasadMDMPH is one of the best medical speakers I have seen. What a loss @ACCP BTW David’s fair/thorough coverage is why I’m a paid subscriber to Silent Lunch
David Zweig@davidzweig

Accusations of "misinformation" were made–many without evidence–against @VPrasadMDMPH as part of a campaign against him speaking at a conference for Clinical Pharmacists (@ACCP). It took less than a day for his invitation to be rescinded. Details here: silentlunch.net/p/after-compla…

Louisville, KY 🇺🇸 English
35
38
254
99.4K
Justin Joy
Justin Joy@HughHFrEFner·
@AnticoagPharmD Not too surprising IMO for a press release. Open label vs riva 20, Phase 2. Stroke & SE werent outcomes. Hopefully phase 3 data is just as promising!
English
0
0
2
85
Justin Joy
Justin Joy@HughHFrEFner·
@RyanCaputo1 Do you recommend switching or discontinuing in your practice? I never rec starting 1cs in CAD, but I'm ok keeping especially if non obstructive and its controlled their AF x many years. CAST was a very specific post MI, low EF, high PVC population without beta blockers
English
1
0
0
150
Ryan Caputo, PharmD, BCCP
Ryan Caputo, PharmD, BCCP@RyanCaputo1·
Despite the conclusion, this study gives me little comfort in using class IC antiarrythmics in nonobstructive CAD. Why was HF hospitalization part of the primary composite when predictably many more HF patients were in the control cohort. jacc.org/doi/abs/10.101…
English
1
2
2
852
Justin Joy
Justin Joy@HughHFrEFner·
@kaulcsmc @soonergise Fair points. I tend to be conservative/"do no harm" if signal in direction of harm, and not seen in other studies of similar populations (that I'm aware) Other IPE studies support, but smaller, open label, Japanese population. These justified lower rec for me
English
0
0
1
26
Justin Joy
Justin Joy@HughHFrEFner·
@kaulcsmc @soonergise How about the signal of increased non-cv deaths in lodoco2? and issues with the mineral oil placebo?
English
3
0
0
71
Sanjay Kaul
Sanjay Kaul@kaulcsmc·
Are GL recs faithful to evidence? Colchicine: Class 2bB (2 + RCTs, why not 1A?) IPE: Class 2bB (REDUCE-IT +ive, RESPECT-EPA borderline, so why not 1B?) SGLT2i for LVEF<40%: 1A & EF>40%: 2aB Why different recs despite similar evidence (PEP driven by HHF)? twitter.com/AHAScience/sta…
AHA Science@AHAScience

🆕 Management of Chronic Coronary Disease Guideline, published today with @ACCInTouch, affirms a heart-healthy diet & lifestyle are the best ways to prevent worsening health for the 20M+ Americans with CCD. #CCDGuideline Read more here: spr.ly/6015PrXZx ✍️ @virani_md

English
1
0
4
1.9K
Gregg Fonarow MD
Gregg Fonarow MD@gcfmd·
🧨 Critical Alert While use of GDMT was ⬆️ at 1 year in patients w/ HFrEF seen in a HF Clinic 💣 63.7% of those eligible for MRA, Still Not Treated Stunning! Clear opportunity for #GDMT performance improvement in every setting @HFSA @JavedButler1 @AndrewJSauer @NMHheartdoc
Gregg Fonarow MD tweet media
Robert Mentz, MD@robmentz

Oct issue of JCF is now available - here's a phenomenal article regarding GDMT in new HFrEF - key role for HF clinics! "GDMT in Newly Diagnosed HFrEF in the Community" @ShannonMDunlay @VeroniqueRoger1 @dranulala @HFSA onlinejcf.com/article/S1071-…

English
3
20
51
0
Justin Joy retweetledi
Harriette Van Spall, MD MPH 🇨🇦
Harriette Van Spall, MD MPH 🇨🇦@hvanspall·
We found that among 1693 pts 🏥 with #HF, simple clinical #phenogroups generated w unsupervised machine learning (hierarchical clustering) stratified outcomes at 6 and 12 months more effectively than #LVEF categories. Valve, lung disease: worst prognosis onlinelibrary.wiley.com/doi/epdf/10.10…
Harriette Van Spall, MD MPH 🇨🇦 tweet mediaHarriette Van Spall, MD MPH 🇨🇦 tweet media
Gregg Fonarow MD@gcfmd

Whether additional or alternative parameters, such as strain, deep phenotyping, biomarker/metabolic/polygenetic profiling, can further improve on the EF based classification, hold promise and should be further studied

English
2
10
34
10.7K

Keşfet

@DrJBhattacharya @MartyMakary @VPrasadMDMPH @CarlosdelRio7 @Rxhaums @EmoryCCRI @accpedtrprn @Sensible__Med